董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas J. Errico | 男 | Chairman of the Board and Director | 74 | 21.50万美元 | 35.23 | 2026-09-08 |
| Julie A. Goldstein | 女 | Director | 67 | 16.25万美元 | 16.81 | 2026-09-08 |
| Patricia Wilber | 女 | Director | 64 | 16.50万美元 | 7.58 | 2026-09-08 |
| Elena Bonfiglioli | 女 | Director | 54 | 16.25万美元 | 0.76 | 2026-09-08 |
| James C. Theofilos | 男 | Director | 31 | 18.00万美元 | 0.88 | 2026-09-08 |
| John P. Gandolfo | 男 | Director | 65 | 17.50万美元 | 8.81 | 2026-09-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joshua S. Lev | 男 | Chief Financial Officer and Interim President | 41 | 70.75万美元 | 2.96 | 2026-09-08 |
| Michael Fox | 男 | Chief Operating Officer | 59 | 未披露 | 未持股 | 2026-09-08 |
董事简历
中英对照 | 中文 | 英文- Thomas J. Errico
-
ThomasJ.Errico自2005年9月以来一直担任我们的董事会成员，当时他与JosephP.Errico和PeterS.Staats共同创立了该公司。Errico博士从1986年开始一直担任董事会认证的整形外科医生，目前担任NYU Langone Health整形外科脊柱外科的部门主管，他从1997年开始担任该职位。他目前也是纽约大学医学院（NYU School of Medicine）骨科和神经外科教授。此外，Errico博士是国际脊柱外科进步协会（International Society for Advancement of Spine Surgery）的成员，并从2010年到2011年担任其总裁。他也是北美脊柱学会（North American Spine Society）的原始成员，并从2003年到2004年担任其总裁。Errico博士在梦百合行业创立了多家公司，包括SpineCore，Inc.，2002年，他在该公司担任董事，直到2004年该公司被出售给Stryker，Inc.。Errico博士还于2004年1月成为K2mGroupHoldings，Inc.的创始成员。Errico博士拥有罗格斯大学（Rutgers University）动物学学士学位和罗格斯医学院（Rutgers Medical School，前身为新泽西医学和牙科大学）的医学博士学位。
Thomas J. Errico is a founder of Electrocore, Inc.'s company and has served as a member of the Board since 2005. Dr. Errico has been a board certified orthopedic surgeon since 1986 and currently serves as a pediatric orthopedic spine surgeon at Nicklaus Children's Hospital since 2018. He also is an associate Professor of Orthopedic Surgery at the University of Miami School of Medicine. He previously served as the chief, Division of Spine Surgery in Orthopedics, at NYU Langone Health from 1997 until 2018 and was an adjunct professor of the Department of Orthopedic Surgery at NYU Grossman School of Medicine. He currently serves on the board of Setting Scoliosis Straight, a nonprofit organization focused on advancing medical techniques in the treatment of spinal deformities. In addition, Dr. Errico is a member of the International Society for the Advancement of Spine Surgery and served as its president from 2010 to 2011. He is also an original member of the North American Spine Society and served as its president from 2003 to 2004. Dr. Errico has founded multiple companies in the healthcare industry, including Spinecore, Inc. in 2001, where he served as a director until it was sold to Stryker, Inc. in 2004. Dr. Errico was also a founding member of K2M Group Holdings, Inc. in January 2004. Dr. Errico holds a B.S. in zoology from Rutgers University and an M.D. from Rutgers Medical School, formerly the University of Medicine and Dentistry of New Jersey. - ThomasJ.Errico自2005年9月以来一直担任我们的董事会成员，当时他与JosephP.Errico和PeterS.Staats共同创立了该公司。Errico博士从1986年开始一直担任董事会认证的整形外科医生，目前担任NYU Langone Health整形外科脊柱外科的部门主管，他从1997年开始担任该职位。他目前也是纽约大学医学院（NYU School of Medicine）骨科和神经外科教授。此外，Errico博士是国际脊柱外科进步协会（International Society for Advancement of Spine Surgery）的成员，并从2010年到2011年担任其总裁。他也是北美脊柱学会（North American Spine Society）的原始成员，并从2003年到2004年担任其总裁。Errico博士在梦百合行业创立了多家公司，包括SpineCore，Inc.，2002年，他在该公司担任董事，直到2004年该公司被出售给Stryker，Inc.。Errico博士还于2004年1月成为K2mGroupHoldings，Inc.的创始成员。Errico博士拥有罗格斯大学（Rutgers University）动物学学士学位和罗格斯医学院（Rutgers Medical School，前身为新泽西医学和牙科大学）的医学博士学位。
- Thomas J. Errico is a founder of Electrocore, Inc.'s company and has served as a member of the Board since 2005. Dr. Errico has been a board certified orthopedic surgeon since 1986 and currently serves as a pediatric orthopedic spine surgeon at Nicklaus Children's Hospital since 2018. He also is an associate Professor of Orthopedic Surgery at the University of Miami School of Medicine. He previously served as the chief, Division of Spine Surgery in Orthopedics, at NYU Langone Health from 1997 until 2018 and was an adjunct professor of the Department of Orthopedic Surgery at NYU Grossman School of Medicine. He currently serves on the board of Setting Scoliosis Straight, a nonprofit organization focused on advancing medical techniques in the treatment of spinal deformities. In addition, Dr. Errico is a member of the International Society for the Advancement of Spine Surgery and served as its president from 2010 to 2011. He is also an original member of the North American Spine Society and served as its president from 2003 to 2004. Dr. Errico has founded multiple companies in the healthcare industry, including Spinecore, Inc. in 2001, where he served as a director until it was sold to Stryker, Inc. in 2004. Dr. Errico was also a founding member of K2M Group Holdings, Inc. in January 2004. Dr. Errico holds a B.S. in zoology from Rutgers University and an M.D. from Rutgers Medical School, formerly the University of Medicine and Dentistry of New Jersey.
- Julie A. Goldstein
-
Julie A. Goldstein自2022年3月起担任董事会成员。Goldstein女士在产品、媒体和娱乐营销方面拥有30多年的领导专长，她的职业生涯涵盖广播、电视、音乐和戏剧。Goldstein女士的专长包括运营、销售开发、广告和项目管理。她还领导了许多重要的国家和国际营销活动。2013年至2014年，她担任百老汇音乐剧《初次约会》的制片人。在JIVE唱片公司、RCA唱片公司和Virgin唱片公司，她担任营销和开发副总裁。她还曾在新闻集团/电视指南电视网担任市场营销和销售副总裁一职，并开始了她的无线电营销职业生涯。她在支出和战略营销技巧方面的专业知识促成了RCA的转型。她获得了公告牌杂志年度电台推广总监、贝塔斯曼关键管理奖和维珍唱片年度推广总监。Goldstein女士拥有加州州立大学奇科分校的通信和社会福利学士学位。
Julie A. Goldstein has served on the Board since March 2022 and has more than 30 years of senior leadership experience in marketing, media, and brand development across music, television, radio, and live entertainment. She was Vice President of Marketing and Development at JIVE Records, RCA Records, and Virgin Records, and Vice President of Marketing and Sales at NewsCorp's TV Guide Television Network, where she led major national and international marketing campaigns and contributed to RCA Records' successful turnaround, work later featured in a Harvard Business School case study. Earlier in her career, Ms. Goldstein was a founding member of the team that launched Live 105 in San Francisco, a pioneering alternative radio station. In early 2026, she was honored by the California Radio Society and the Bay Area Radio Museum and Hall of Fame with a Founding Member Legends / Lifetime Achievement recognition for her role in the station's creation and lasting impact. She is also a Broadway producer and has received multiple industry honors, including Billboard Magazine's Radio Promotion Director of the Year and the Bertelsmann Key Management Award. She holds a B.A. in Communications and Social Welfare from California State University, Chico. - Julie A. Goldstein自2022年3月起担任董事会成员。Goldstein女士在产品、媒体和娱乐营销方面拥有30多年的领导专长，她的职业生涯涵盖广播、电视、音乐和戏剧。Goldstein女士的专长包括运营、销售开发、广告和项目管理。她还领导了许多重要的国家和国际营销活动。2013年至2014年，她担任百老汇音乐剧《初次约会》的制片人。在JIVE唱片公司、RCA唱片公司和Virgin唱片公司，她担任营销和开发副总裁。她还曾在新闻集团/电视指南电视网担任市场营销和销售副总裁一职，并开始了她的无线电营销职业生涯。她在支出和战略营销技巧方面的专业知识促成了RCA的转型。她获得了公告牌杂志年度电台推广总监、贝塔斯曼关键管理奖和维珍唱片年度推广总监。Goldstein女士拥有加州州立大学奇科分校的通信和社会福利学士学位。
- Julie A. Goldstein has served on the Board since March 2022 and has more than 30 years of senior leadership experience in marketing, media, and brand development across music, television, radio, and live entertainment. She was Vice President of Marketing and Development at JIVE Records, RCA Records, and Virgin Records, and Vice President of Marketing and Sales at NewsCorp's TV Guide Television Network, where she led major national and international marketing campaigns and contributed to RCA Records' successful turnaround, work later featured in a Harvard Business School case study. Earlier in her career, Ms. Goldstein was a founding member of the team that launched Live 105 in San Francisco, a pioneering alternative radio station. In early 2026, she was honored by the California Radio Society and the Bay Area Radio Museum and Hall of Fame with a Founding Member Legends / Lifetime Achievement recognition for her role in the station's creation and lasting impact. She is also a Broadway producer and has received multiple industry honors, including Billboard Magazine's Radio Promotion Director of the Year and the Bertelsmann Key Management Award. She holds a B.A. in Communications and Social Welfare from California State University, Chico.
- Patricia Wilber
-
Patricia Wilber自2022年3月起担任董事会成员。Wilber女士一直担任首席营销官、全球业务战略家和董事会成员，负责为品牌提供组织和文化转型。她是新的特许经营模式和品牌合作伙伴关系的先驱。威尔伯上次担任欧洲、中东和非洲地区合作伙伴关系执行副总裁、首席营销官兼董事总经理的职位是在2015年至2018年，这是迪士尼市场部的最高职位，在那里她通过领导迪士尼、皮克斯、星球大战和漫威的营销和传播，推动了沃尔特迪斯尼公司旗下知名品牌的增长。此外，她还建立并领导了欧洲、中东和非洲地区40个国家的综合营销、特许经营和伙伴关系职能，包括对欧洲、中东和非洲地区渠道的重大重组，以通过大幅削减开支来促进增长和盈利。她曾于2015年至2018年担任欧洲迪士尼公司的董事会成员，并于2013年至2018年担任神奇游轮公司的董事会成员，该公司通常被称为迪士尼游轮公司。Wilber女士拥有布朗大学历史学学士学位。
Patricia Wilber has served as a member of the Board since March 2022. Ms. Wilber has been a chief marketing officer, global business strategist, and board member who delivers organizational and cultural transformation for branding. She is a pioneer in new franchise models and branded partnerships. Ms. Wilber last served as the executive vice president, chief marketing officer, and managing director of partnerships, EMEA, the highest position in the marketing department at The Walt Disney Company from 2015 to 2018, where she drove growth for Disney's marquee brands by leading marketing and communications for Disney, Pixar, Star Wars, and Marvel. Additionally, she established and led EMEA's 40 country integrated marketing, franchise and partnership functions, including a major reorganization of the EMEA channels to boost growth and profitability by significantly reducing expenses. She currently serves on the board of Zapp Electric Vehicles Group Limited. She also serves on the board and is the chair of the nominating and governance executive committee of Yale New Haven Hospital, a medical nonprofit organization, and chairs the nominating and governance committee, and on the patient safety committee of Yale New Haven Health System. She served on the boards of Euro Disney SCA from 2015 to 2018, Magical Cruise Company, more commonly known as the Disney Cruise Line, from 2013 to 2018, and Vibrant Emotional Health from 2022 to 2023. Ms. Wilber holds a B.A. in history from Brown University. - Patricia Wilber自2022年3月起担任董事会成员。Wilber女士一直担任首席营销官、全球业务战略家和董事会成员，负责为品牌提供组织和文化转型。她是新的特许经营模式和品牌合作伙伴关系的先驱。威尔伯上次担任欧洲、中东和非洲地区合作伙伴关系执行副总裁、首席营销官兼董事总经理的职位是在2015年至2018年，这是迪士尼市场部的最高职位，在那里她通过领导迪士尼、皮克斯、星球大战和漫威的营销和传播，推动了沃尔特迪斯尼公司旗下知名品牌的增长。此外，她还建立并领导了欧洲、中东和非洲地区40个国家的综合营销、特许经营和伙伴关系职能，包括对欧洲、中东和非洲地区渠道的重大重组，以通过大幅削减开支来促进增长和盈利。她曾于2015年至2018年担任欧洲迪士尼公司的董事会成员，并于2013年至2018年担任神奇游轮公司的董事会成员，该公司通常被称为迪士尼游轮公司。Wilber女士拥有布朗大学历史学学士学位。
- Patricia Wilber has served as a member of the Board since March 2022. Ms. Wilber has been a chief marketing officer, global business strategist, and board member who delivers organizational and cultural transformation for branding. She is a pioneer in new franchise models and branded partnerships. Ms. Wilber last served as the executive vice president, chief marketing officer, and managing director of partnerships, EMEA, the highest position in the marketing department at The Walt Disney Company from 2015 to 2018, where she drove growth for Disney's marquee brands by leading marketing and communications for Disney, Pixar, Star Wars, and Marvel. Additionally, she established and led EMEA's 40 country integrated marketing, franchise and partnership functions, including a major reorganization of the EMEA channels to boost growth and profitability by significantly reducing expenses. She currently serves on the board of Zapp Electric Vehicles Group Limited. She also serves on the board and is the chair of the nominating and governance executive committee of Yale New Haven Hospital, a medical nonprofit organization, and chairs the nominating and governance committee, and on the patient safety committee of Yale New Haven Health System. She served on the boards of Euro Disney SCA from 2015 to 2018, Magical Cruise Company, more commonly known as the Disney Cruise Line, from 2013 to 2018, and Vibrant Emotional Health from 2022 to 2023. Ms. Wilber holds a B.A. in history from Brown University.
- Elena Bonfiglioli
-
Elena Bonfiglioli，自2022年1月起担任微软公司（“微软”）医疗保健、医药生命科学领域的全球业务负责人。在担任这一职务期间，Bonfiglioli女士负责全球范围内医疗保健提供者、支付者和生命科学组织在人工智能转型方面的上市、商业、管道开发和战略合作伙伴关系。自2017年8月以来，Bonfiglioli女士还担任微软欧洲中东非洲（“EMEA”）地区健康和生命科学区域业务负责人。此前，Bonfiglioli女士曾在微软担任其他职务，包括担任欧洲、中东和非洲地区健康产业高级总监。自2023年以来，Bonfiglioli女士一直是欧洲、中东和非洲药品信息协会（DIA）药品咨询委员会的成员。Bonfiglioli女士还不时担任私营生物制药和医疗技术组织的顾问。Bonfiglioli女士拥有欧洲学院欧洲经济学硕士学位、Moderna大学商业和管理经济学Laurea学位以及蒙彼利埃大学应用经济学执照学位。
Elena Bonfiglioli has been the Global Business Leader for Healthcare, Pharma Life Sciences of Microsoft since January 2022. In this role, Ms. Bonfiglioli is responsible for go to market, commercial, pipeline development and strategic partnerships in artificial intelligence transformation across health providers, payors and life sciences' organizations globally. Ms. Bonfiglioli has also been the Regional Business Leader for Health and Life Sciences of Microsoft's Europe Middle East Africa ("EMEA") region since August 2017. Previously, Ms. Bonfiglioli held other positions at Microsoft, including as Senior Director – Health Industry of the EMEA region. Since 2023, Ms. Bonfiglioli has been a member of the Drug Information Association (DIA) Pharma Advisory Council for EMEA. From time to time, Ms. Bonfiglioli has also served as an advisor to private biopharma and medtech organizations. She is on the Advisory Board of Kearney Women Health community initiative and sits in the Board of Care since July 2025. Ms. Bonfiglioli holds a master's degree in European economics from the College of Europe, a Laurea Degree in Business and Managerial Economics from the University of Modena, and a Licentiate Degree in applied economics from the University of Montpellier. - Elena Bonfiglioli，自2022年1月起担任微软公司（“微软”）医疗保健、医药生命科学领域的全球业务负责人。在担任这一职务期间，Bonfiglioli女士负责全球范围内医疗保健提供者、支付者和生命科学组织在人工智能转型方面的上市、商业、管道开发和战略合作伙伴关系。自2017年8月以来，Bonfiglioli女士还担任微软欧洲中东非洲（“EMEA”）地区健康和生命科学区域业务负责人。此前，Bonfiglioli女士曾在微软担任其他职务，包括担任欧洲、中东和非洲地区健康产业高级总监。自2023年以来，Bonfiglioli女士一直是欧洲、中东和非洲药品信息协会（DIA）药品咨询委员会的成员。Bonfiglioli女士还不时担任私营生物制药和医疗技术组织的顾问。Bonfiglioli女士拥有欧洲学院欧洲经济学硕士学位、Moderna大学商业和管理经济学Laurea学位以及蒙彼利埃大学应用经济学执照学位。
- Elena Bonfiglioli has been the Global Business Leader for Healthcare, Pharma Life Sciences of Microsoft since January 2022. In this role, Ms. Bonfiglioli is responsible for go to market, commercial, pipeline development and strategic partnerships in artificial intelligence transformation across health providers, payors and life sciences' organizations globally. Ms. Bonfiglioli has also been the Regional Business Leader for Health and Life Sciences of Microsoft's Europe Middle East Africa ("EMEA") region since August 2017. Previously, Ms. Bonfiglioli held other positions at Microsoft, including as Senior Director – Health Industry of the EMEA region. Since 2023, Ms. Bonfiglioli has been a member of the Drug Information Association (DIA) Pharma Advisory Council for EMEA. From time to time, Ms. Bonfiglioli has also served as an advisor to private biopharma and medtech organizations. She is on the Advisory Board of Kearney Women Health community initiative and sits in the Board of Care since July 2025. Ms. Bonfiglioli holds a master's degree in European economics from the College of Europe, a Laurea Degree in Business and Managerial Economics from the University of Modena, and a Licentiate Degree in applied economics from the University of Montpellier.
- James C. Theofilos
-
自2025年10月以来，James C. Theofilos一直是Google Cloud的人工智能能力上市（“GTM”）负责人。在这个职位上，Theofilos先生负责管理和推动vario biness功能，包括GPU和TPU分配、Google Gemini出货量和生命周期，以及全球范围内的普遍可用性。从2023年10月到2025年9月，Theofilos先生是微软公司（“微软”）Azure和人工智能部门的高级财务经理。在微软担任这一职务时，Theofilos先生是微软AI Apps & Agents团队的GTM财务负责人，该团队包括微软所有的AI模型、GitHub Copilot、Copilot Studio和其他产品。Previoly，Theofilos先生在微软担任过多个财务职位，包括担任微软全球医疗保健和生命科学销售团队的财务主管，该团队包括接触健康提供者、支付者、制药和医疗技术行业垂直领域。在此之前，Theofilos先生在VICI Properties Inc.担任集团项目经理，该公司是一家公开交易的房地产投资信托公司，主要从事拥有和收购博彩、酒店、休闲、娱乐和休闲目的地的业务，总部位于纽约市。Theofilos先生拥有圣路易斯华盛顿大学金融学硕士学位和金融学学士学位。
James C. Theofilos has been the Artificial Intelligence Capacity Go to Market ("GTM") Lead at Google Cloud since October 2025. In this role, Mr. Theofilos manages and drives various business functions, including Graphics Processing Unit and Tensor Processing Unit allocations, Google Gemini shipments and lifecycles, as well as general availability across the globe. From October 2023 to September 2025, Mr. Theofilos was a Senior Finance Manager within the Azure and artificial intelligence division of Microsoft Corporation ("Microsoft"). In this role at Microsoft, Mr. Theofilos was the GTM Finance Lead across Microsoft's AI Apps & Agents team, which includes all of Microsoft's AI models, GitHub Copilot, Copilot Studio, and other products. Previously, Mr. Theofilos held various finance positions at Microsoft including his position as the Finance Lead for Microsoft's Global Healthcare & Life Sciences Sales team, which included exposure to the Health Providers, Payors, Pharma and Med Tech industry verticals. Prior to that, Mr. Theofilos consulted as a Group Project Manager at VICI Properties Inc., a publicly traded Real Estate Investment Trust primarily engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment, and leisure destinations, based in New York City. Mr. Theofilos holds an M.S. in Finance and a B.S.B.A. in Finance from Washington University in Saint Louis. - 自2025年10月以来，James C. Theofilos一直是Google Cloud的人工智能能力上市（“GTM”）负责人。在这个职位上，Theofilos先生负责管理和推动vario biness功能，包括GPU和TPU分配、Google Gemini出货量和生命周期，以及全球范围内的普遍可用性。从2023年10月到2025年9月，Theofilos先生是微软公司（“微软”）Azure和人工智能部门的高级财务经理。在微软担任这一职务时，Theofilos先生是微软AI Apps & Agents团队的GTM财务负责人，该团队包括微软所有的AI模型、GitHub Copilot、Copilot Studio和其他产品。Previoly，Theofilos先生在微软担任过多个财务职位，包括担任微软全球医疗保健和生命科学销售团队的财务主管，该团队包括接触健康提供者、支付者、制药和医疗技术行业垂直领域。在此之前，Theofilos先生在VICI Properties Inc.担任集团项目经理，该公司是一家公开交易的房地产投资信托公司，主要从事拥有和收购博彩、酒店、休闲、娱乐和休闲目的地的业务，总部位于纽约市。Theofilos先生拥有圣路易斯华盛顿大学金融学硕士学位和金融学学士学位。
- James C. Theofilos has been the Artificial Intelligence Capacity Go to Market ("GTM") Lead at Google Cloud since October 2025. In this role, Mr. Theofilos manages and drives various business functions, including Graphics Processing Unit and Tensor Processing Unit allocations, Google Gemini shipments and lifecycles, as well as general availability across the globe. From October 2023 to September 2025, Mr. Theofilos was a Senior Finance Manager within the Azure and artificial intelligence division of Microsoft Corporation ("Microsoft"). In this role at Microsoft, Mr. Theofilos was the GTM Finance Lead across Microsoft's AI Apps & Agents team, which includes all of Microsoft's AI models, GitHub Copilot, Copilot Studio, and other products. Previously, Mr. Theofilos held various finance positions at Microsoft including his position as the Finance Lead for Microsoft's Global Healthcare & Life Sciences Sales team, which included exposure to the Health Providers, Payors, Pharma and Med Tech industry verticals. Prior to that, Mr. Theofilos consulted as a Group Project Manager at VICI Properties Inc., a publicly traded Real Estate Investment Trust primarily engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment, and leisure destinations, based in New York City. Mr. Theofilos holds an M.S. in Finance and a B.S.B.A. in Finance from Washington University in Saint Louis.
- John P. Gandolfo
-
John P. Gandolfo，自2013年10月起担任董事。他拥有大约33年的经验，担任多家快速增长的私人和上市公司的首席财务官（“CFO”），主要关注生命科学、医疗保健和医疗设备领域。在他的职业生涯中，他直接负责融资，包括五次公开发行、财务管理、并购交易和SEC报告。从2018年1月至今，他担任Eyenovia， Inc. （EYEN）的首席财务官，EYEN是一家后期眼科生物制药公司。在此之前，他从2010年7月到2017年9月担任生物制剂公司Xtant Medical Holdings， Inc.的首席财务官。在此之前，从2009年1月到2010年6月，他担任Progenitor Cell Therapy LLC的首席财务官。在此之前，从2007年1月到2009年1月，他担任Power Medical Interventions， Inc.的首席财务官。在此之前，他是Bioject Medical Technologies， Inc.的首席财务官。2000年至2001年9月，他担任Capital Access Network， Inc.的首席财务官；1999年至2000年，他担任Xceed， Inc.的首席财务官。从1994年到1999年，他担任Impath， Inc.的首席财务官和首席运营官。从1987年到1994年，他担任Medical Resources， Inc.的首席财务官。Gandolfo先生此前于2019年至2023年担任Odyssey Health， Inc.（奥德赛集团国际公司）的董事会成员，并担任审计委员会主席。Gandolfo先生目前是Electrocore， Inc. （ECOR）的董事会成员，薪酬委员会主席和审计委员会成员。他持有Rutgers大学的工商管理学士学位。
John P. Gandolfo has served as a member of the Board since April 2020. He has to the Board more than 30 years of financial leadership at both public and private companies across multiple industry sectors, including in expense control and cash flow optimization having retired in 2024 as chief financial officer of Eyenovia, Inc., a publicly held, late clinical stage biopharmaceutical company focusing on the development of ophthalmic drugs. Prior to Eyenovia, he served as chief financial officer of Xtant Medical Holdings, Inc., a publicly held orthopedic and spine medical device company with multiple operations throughout the United States from 2010 to 2017. He has served on the board of Oragenics, Inc, a clinical stage biopharma company developing concussion and other neurological drugs, since September 2023. His prior healthcare related experience includes roles as chief financial officer of Progenitor Cell Therapy LLC, Power Medical Interventions and Bioject, Inc., among others. Mr. Gandolfo's experience also includes serving on the audit committees of the boards of multiple medical technology companies including Odyssey Health, Inc., a medical device company which he served as a director from 2019 to 2023. Mr. Gandolfo holds a B.A. in business administration from Rutgers University. - John P. Gandolfo，自2013年10月起担任董事。他拥有大约33年的经验，担任多家快速增长的私人和上市公司的首席财务官（“CFO”），主要关注生命科学、医疗保健和医疗设备领域。在他的职业生涯中，他直接负责融资，包括五次公开发行、财务管理、并购交易和SEC报告。从2018年1月至今，他担任Eyenovia， Inc. （EYEN）的首席财务官，EYEN是一家后期眼科生物制药公司。在此之前，他从2010年7月到2017年9月担任生物制剂公司Xtant Medical Holdings， Inc.的首席财务官。在此之前，从2009年1月到2010年6月，他担任Progenitor Cell Therapy LLC的首席财务官。在此之前，从2007年1月到2009年1月，他担任Power Medical Interventions， Inc.的首席财务官。在此之前，他是Bioject Medical Technologies， Inc.的首席财务官。2000年至2001年9月，他担任Capital Access Network， Inc.的首席财务官；1999年至2000年，他担任Xceed， Inc.的首席财务官。从1994年到1999年，他担任Impath， Inc.的首席财务官和首席运营官。从1987年到1994年，他担任Medical Resources， Inc.的首席财务官。Gandolfo先生此前于2019年至2023年担任Odyssey Health， Inc.（奥德赛集团国际公司）的董事会成员，并担任审计委员会主席。Gandolfo先生目前是Electrocore， Inc. （ECOR）的董事会成员，薪酬委员会主席和审计委员会成员。他持有Rutgers大学的工商管理学士学位。
- John P. Gandolfo has served as a member of the Board since April 2020. He has to the Board more than 30 years of financial leadership at both public and private companies across multiple industry sectors, including in expense control and cash flow optimization having retired in 2024 as chief financial officer of Eyenovia, Inc., a publicly held, late clinical stage biopharmaceutical company focusing on the development of ophthalmic drugs. Prior to Eyenovia, he served as chief financial officer of Xtant Medical Holdings, Inc., a publicly held orthopedic and spine medical device company with multiple operations throughout the United States from 2010 to 2017. He has served on the board of Oragenics, Inc, a clinical stage biopharma company developing concussion and other neurological drugs, since September 2023. His prior healthcare related experience includes roles as chief financial officer of Progenitor Cell Therapy LLC, Power Medical Interventions and Bioject, Inc., among others. Mr. Gandolfo's experience also includes serving on the audit committees of the boards of multiple medical technology companies including Odyssey Health, Inc., a medical device company which he served as a director from 2019 to 2023. Mr. Gandolfo holds a B.A. in business administration from Rutgers University.
高管简历
中英对照 | 中文 | 英文- Joshua S. Lev
Joshua S. Lev自2024年10月起担任electroCore, Inc.的首席财务官，自2026年4月起担任electroCore, Inc.的临时总裁。列夫先生于2022年1月至2024年10月担任公司首席战略官，此前于2020年2月至2022年1月担任业务发展、战略和财务规划副总裁。在加入公司之前，Lev先生在金融服务行业工作了超过15年，担任投资银行家和投资者，专注于新兴成长型公司。2011年至2020年2月，Lev先生担任Wellfleet Partners，Inc.业务发展总监，专注于融资、并购、战略交易和机构客户关系。从2014年3月到2020年2月，他是Aracle Capital，LLC的联合创始人，这是一家专注于早期和新兴成长型公司的投资公司。列夫先生获得了北卡罗来纳大学凯南·弗拉格勒商学院的工商管理硕士学位和叶史瓦大学SY Syms商学院的商业与管理学士学位。
Joshua S. Lev has served as Electrocore, Inc.'s Chief Financial Officer since October 2024, and as Electrocore, Inc.'s Interim President since April 2026. Mr. Lev served as the Chief Strategy Officer of the Company from January 2022 to October 2024, previously serving as Vice President of Business Development, Strategy and Financial Planning from February 2020 to January 2022. Prior to joining the Company, Mr. Lev worked for greater than 15 years in the financial services industry as an investment banker and investor focusing on emerging growth companies. From 2011 to February 2020, Mr. Lev served as Director of Business Development at Wellfleet Partners, Inc. focusing on capital raising, M&A, strategic transactions and institutional client relations. From March 2014 through February 2020, he was a co founder of Aracle Capital, LLC, an investment firm with a focus on early stage and emerging growth companies. Mr. Lev received an M.B.A. from the University of North Carolina's Kenan Flagler Business School and a B.S. in Business & Management from the Sy Syms School of Business at Yeshiva University.- Joshua S. Lev自2024年10月起担任electroCore, Inc.的首席财务官，自2026年4月起担任electroCore, Inc.的临时总裁。列夫先生于2022年1月至2024年10月担任公司首席战略官，此前于2020年2月至2022年1月担任业务发展、战略和财务规划副总裁。在加入公司之前，Lev先生在金融服务行业工作了超过15年，担任投资银行家和投资者，专注于新兴成长型公司。2011年至2020年2月，Lev先生担任Wellfleet Partners，Inc.业务发展总监，专注于融资、并购、战略交易和机构客户关系。从2014年3月到2020年2月，他是Aracle Capital，LLC的联合创始人，这是一家专注于早期和新兴成长型公司的投资公司。列夫先生获得了北卡罗来纳大学凯南·弗拉格勒商学院的工商管理硕士学位和叶史瓦大学SY Syms商学院的商业与管理学士学位。
- Joshua S. Lev has served as Electrocore, Inc.'s Chief Financial Officer since October 2024, and as Electrocore, Inc.'s Interim President since April 2026. Mr. Lev served as the Chief Strategy Officer of the Company from January 2022 to October 2024, previously serving as Vice President of Business Development, Strategy and Financial Planning from February 2020 to January 2022. Prior to joining the Company, Mr. Lev worked for greater than 15 years in the financial services industry as an investment banker and investor focusing on emerging growth companies. From 2011 to February 2020, Mr. Lev served as Director of Business Development at Wellfleet Partners, Inc. focusing on capital raising, M&A, strategic transactions and institutional client relations. From March 2014 through February 2020, he was a co founder of Aracle Capital, LLC, an investment firm with a focus on early stage and emerging growth companies. Mr. Lev received an M.B.A. from the University of North Carolina's Kenan Flagler Business School and a B.S. in Business & Management from the Sy Syms School of Business at Yeshiva University.
- Michael Fox
Michael Fox自2026年4月起担任electroCore, Inc.的首席运营官。从2023年7月到2026年3月，福克斯先生担任ProMedTek，Inc.的首席营收官，ProMedTek，Inc.是一家私营医疗技术公司。在此之前，Fox先生于2019年1月至2023年6月在辉瑞公司担任罕见病领域业务经理。福克斯先生在医疗销售领域担任过其他各种职务。Fox先生的职业生涯始于辉瑞公司，从1990年至2009年，他曾在该公司担任过各种职务。自2019年10月以来，Mr. Fox还担任V Locity Medical Consulting的医疗顾问。福克斯先生在西伊利诺伊大学获得了动物科学学士学位。
Michael Fox has served Electrocore, Inc.'s Chief Operating Officer since April 2026. From July 2023 to March 2026, Mr. Fox was the Chief Revenue Officer of ProMedTek, Inc., a privately held medical technology company. Prior to that, Mr. Fox was a rare diseases area business manager at Pfizer, Inc. from January 2019 to June 2023. Mr. Fox has held various other roles in the medical sales field. Mr. Fox began his career at Pfizer, Inc. where he served in various roles from 1990 to 2009. Mr. Fox has also been a medical consultant for V Locity Medical Consulting since October 2019. Mr. Fox received a B.S. in Animal Science from Western Illinois University.- Michael Fox自2026年4月起担任electroCore, Inc.的首席运营官。从2023年7月到2026年3月，福克斯先生担任ProMedTek，Inc.的首席营收官，ProMedTek，Inc.是一家私营医疗技术公司。在此之前，Fox先生于2019年1月至2023年6月在辉瑞公司担任罕见病领域业务经理。福克斯先生在医疗销售领域担任过其他各种职务。Fox先生的职业生涯始于辉瑞公司，从1990年至2009年，他曾在该公司担任过各种职务。自2019年10月以来，Mr. Fox还担任V Locity Medical Consulting的医疗顾问。福克斯先生在西伊利诺伊大学获得了动物科学学士学位。
- Michael Fox has served Electrocore, Inc.'s Chief Operating Officer since April 2026. From July 2023 to March 2026, Mr. Fox was the Chief Revenue Officer of ProMedTek, Inc., a privately held medical technology company. Prior to that, Mr. Fox was a rare diseases area business manager at Pfizer, Inc. from January 2019 to June 2023. Mr. Fox has held various other roles in the medical sales field. Mr. Fox began his career at Pfizer, Inc. where he served in various roles from 1990 to 2009. Mr. Fox has also been a medical consultant for V Locity Medical Consulting since October 2019. Mr. Fox received a B.S. in Animal Science from Western Illinois University.